The Relative Efficacy of Meperidine for the Treatment of Acute Migraine: A Meta-analysis of Randomized Controlled Trials

Department of Emergency Medicine, Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Annals of emergency medicine (Impact Factor: 4.68). 12/2008; 52(6):705-13. DOI: 10.1016/j.annemergmed.2008.05.036
Source: PubMed


Despite guidelines recommending against opioids as first-line treatment for acute migraine, meperidine is the agent used most commonly in North American emergency departments. Clinical trials performed to date have been small and have not arrived at consistent conclusions about the efficacy of meperidine. We performed a systematic review and meta-analysis to determine the relative efficacy and adverse effect profile of opioids compared with nonopioid active comparators for the treatment of acute migraine.
We searched multiple sources (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, and LILACS, emergency and headache medicine conference proceedings) for randomized controlled trials comparing parenteral opioid and nonopioid active comparators for the treatment of acute migraine headache. Our primary outcome was relief of headache. If this was unavailable, we accepted rescue medication use or we transformed visual analog scale change scores by using an established procedure. We grouped studies by comparator: a regimen containing dihydroergotamine, antiemetic alone, or ketorolac. For each study, we calculated an odds ratio (OR) of headache relief and then assessed clinical and statistical heterogeneity for the group of studies. We then pooled the ORs of headache relief with a random-effects model.
From 899 citations, 19 clinical trials were identified, of which 11 were appropriate and had available data. Four trials involving 254 patients compared meperidine to dihydroergotamine, 4 trials involving 248 patients compared meperidine to an antiemetic, and 3 trials involving 123 patients compared meperidine to ketorolac. Meperidine was less effective than dihydroergotamine at providing headache relief (OR=0.30; 95% confidence interval [CI] 0.09 to 0.97) and trended toward less efficacy than the antiemetics (OR=0.46; 95% CI 0.19 to 1.11); however, the efficacy of meperidine was similar to that of ketorolac (OR=1.75; 95% CI 0.84 to 3.61). Compared to dihydroergotamine, meperidine caused more sedation (OR=3.52; 95% CI 0.87 to 14.19) and dizziness (OR=8.67; 95% CI 2.66 to 28.23). Compared to the antiemetics, meperidine caused less akathisia (OR=0.10; 95% CI 0.02 to 0.57). Meperidine and ketorolac use resulted in similar rates of gastrointestinal adverse effects (OR=1.27; 95% CI 0.31 to 5.15) and sedation (OR=1.70; 95% CI 0.23 to 12.72).
Clinicians should consider alternatives to meperidine when treating acute migraine with injectable agents.

Download full-text


Available from: Benjamin W Friedman
  • Source
    • "Moreover, migraine patients [13, 81, 82] and also chronic daily headache patients [83] were considered poorly responsive to opioid drugs and more sensitive to their side effects [82, 84]. Also, mepheridine was less effective than other antimigraine drugs such as dihydroergotamine and antiemetics, and in many trials it was co-administered with antihistamines which may enhance its efficacy [85]. Curiously, it was shown that a genetic variation may be responsible of the intolerable side effects or inadequate analgesia produced by morphine in 10–30% of cancer patients [86]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The original Wolff's vascular theory of migraine was supported by the discovery of a class of drugs, the triptans, developed as a selective cephalic vasoconstrictor agents. Even in the neurovascular hypothesis of Moskowitz, that is the neurogenic inflammation of meningeal vessels provoked by peptides released from trigeminal sensory neurons, the vasodilatation provoked by calcitonin gene-related peptide (CGRP) is considered today much more important than oedema. The role of cephalic vasodilatation as a cause of migraine pain was recently sustained by studies showing the therapeutic effect of CGRP receptor antagonists. We discuss the evidence against vasodilatation as migraine pain generator and some findings which we suggest in support of a central (brain) origin of pain.
    Preview · Article · Jul 2009 · The Journal of Headache and Pain
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: . We continue our investigation of finite element approximations to the system of shallow water equations, based on the generalized wave continuity equation (GWCE) formulation. In previous work, we analyzed this system assuming Dirichlet boundary conditions on both elevation and velocity. Based on physical grounds, it is possible to not impose boundary conditions on elevation. Thus, we examine the formulation for the case of Dirichlet conditions on velocity only. The changes required to the finite element method are presented, and stability and error estimates are derived for both an approximate linear model and a full nonlinear model, assuming continous time. Stability for a discrete time method is also shown. Key words. boundary conditions, shallow water equations, wave shallow water equations, error estimates AMS subject classifications. 35Q35, 35L65 65N30, 65N15 1. Introduction. In this paper, we continue our investigation of finite element methods applied to the GWCE (Generaliz...
    Full-text · Article · Oct 1998 · SIAM Journal on Numerical Analysis
  • [Show abstract] [Hide abstract]
    ABSTRACT: The World Health Organization (WHO) placed migraine 19th among all causes of disability (12th in women) measured in years of healthy life lost to disability (YLD). The importance of headache disorders, particularly of the primary forms, is established by their distribution worldwide, their duration (the majority being life-long conditions) and their imposition of both disability and life-style restrictions among large numbers of people. For these reasons, headache disorders should represent a public-health priority. In the Emergency Department (ED), as elsewhere, migraine is often under-diagnosed-and under-treated when it is diagnosed. The result is likely to be failure of treatment. Particular attention to diagnosis is needed in ED patients with acute headache, since there is a higher probability of secondary headache due to underlying pathologies. According to European principles of management, acute migraine treatment generally is stepwise. Of the two main steps, the first relies on symptomatic medication, preferably NSAIDs with or without antiemetics. The second step uses specific therapies, usually triptans. Modifications to routine practice are appropriate in the ED. Parenteral administration of symptomatic therapies is a preferred first choice, whilst immediate resort to triptans may be appropriate, and achieve better outcomes, in patients with severe headache and diagnostic confirmation of migraine.
    No preview · Article · Oct 2008 · Internal and Emergency Medicine
Show more